Compound ID | 1804
Synonym(s): ASN200 program
Class: Antibody (monoclonal antibody [mAb])
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against E. coli. ASN-4 is directly bactericidal and provides anti-inflammatory effects |
| Description: | Humanized monoclonal antibody |
| Institute where first reported: | BB100, LLC (subsidiary of Bravos Biosciences), Arsanis |
| Year first mentioned: | 2018 |
| Highest developmental phase: | Preclinical |
| Development status: | Active (as of 2022) |